Belgian mRNA and lipid nanoparticle (LNP) technology provider etherna has announced that the early-stage biotech Dropshot Therapeutics will be using the brand's platform for manufacturing and producing GMP-grade material for IND-enabling studies and intended Phase I clinical trials.
The duo will be advancing a renal disease programme from Dropshot.
In its statement, etherna said that the decision marked a "major milestone" in the ongoing partnership between the pair.
"We are pleased to see that Dropshot has achieved its preclinical milestones based on our nucleic acid and LNP platforms and has decided to move to the next steps," said Bernard Sagaert, CEO of etherna.
We will now support them fully in all manufacturing and regulatory steps needed to launch the clinical campaign in 2027.
"Dropshot Therapeutics is committed to advancing innovation to address unmet medical needs in renal and cardiac diseases," added Marijn Dekkers, CEO of Dropshot.
We are very pleased with the results we have obtained. We are delighted to see the rapid progress of our collaboration, based on etherna's nucleic acid and LNP capabilities.